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Editors: Anton N. Sidawy and Bruce A. PerlerComparison of fenestrated endografts and the snorkel/
chimney technique
Jason T., Lee, George K., Lee,Venita Chandra Ronald L., Dalman
Objective: Recent approval by the Food and Drug Admin-
istration of custom fenestrated endografts has increased
endovascular options for patients with short-neck or jux-
tarenal abdominal aortic aneurysms (AAAs). We sought to
compare the early learning curve at a single institution of
fenestrated repair vs the snorkel technique.
Methods: From 2009 to 2013, we performed 57 consec-
utive snorkel procedures for juxtarenal AAAs in an Institu-
tional Review Board-approved prospective cohort, and since
the summer of 2012, we gained access to the Food and
Drug Administration-approved custom fenestrated device.
Patient demographics, imaging, and operative techniques
were compared between the ﬁrst 15 cases for each of the
snorkel (sn-EVAR) and fenestrated (f-EVAR) endovascular
aneurysm repair (EVAR) techniques.
Results: Patient demographics and AAA morphology on
preoperative imaging were similar between the groups.
Operative time tended to be similar in the 3- to 4-hour range,
withmore ﬂuoroscopy time and less contrastmaterial used in
f-EVAR than in sn-EVAR (P < .05) because of differing strat-
egies of renal premarking. Larger delivery systems for f-EVAR
required a higher rate of iliac conduits (40% vs 0%). Peri-
operative complications, short-term renal patency rates, and
evidence of acute kidney injury were similar.
Conclusions: The early experience of f-EVAR was similar to
that of sn-EVAR in terms of patient demographics, case
selection, and procedural characteristics. A signiﬁcant por-
tion of the learning curve for both procedures, particularly
for f-EVAR, lies in the preoperative planning of fenestrations
and the cannulation of branch vessels. Similar short-term
postoperative outcomes between these two particular
techniques indicate that both will have utility in the treat-
ment of high-risk patients with complex anatomy.Results of the ANCHOR prospective, multicenter registry of
EndoAnchors for type Ia endoleaks and endograft
migration in patients with challenging anatomy
William D., Jordan, Manish Mehta, David Varnagy,
William M., Moore, Frank R., Arko, James Joye,
Kenneth Ouriel, Jean-Paul de Vries
Objective: Proximal attachment site complications continue
to occur after endovascular repair of abdominal aortic*Full articles available online at www.jvascsurg.org
1078-5884/$ e see front matter
http://dx.doi.org/10.1016/S1078-5884(14)00497-3aneurysms (EVAR), speciﬁcally type Ia endoleak and endog-
raft migration. EndoAnchors (Aptus Endosystems, Sunnyvale,
Calif) were designed to enhance endograft proximal ﬁxation
and sealing, and the current study was undertaken to eval-
uate the potential beneﬁt of this treatment.
Methods: During the 23-month period ending in December
2013, 319 subjects were enrolled at 43 sites in the United
States and Europe. EndoAnchors were implanted in 242
patients (75.9%) at the time of an initial EVAR procedure
(primary arm) and in 77 patients with an existing endograft
and proximal aortic neck complications (revision arm).
Technical success was deﬁned as deployment of the desired
number of EndoAnchors, adequate penetration of the ves-
sel wall, and absence of EndoAnchor fracture. Procedural
success was deﬁned as technical success without a type Ia
endoleak at completion angiography. Values are expressed
as mean  standard deviation and interquartile range.
Results: The 238male (74.6%) and 81 female (25.4%) subjects
had amean age of 74.1 8.2 years. Aneurysms averaged58
13 (51-63) mm in diameter at the time of EndoAnchor
implantation (core laboratory measurements). The proximal
aortic neck averaged 16  13 (7-23) mm in length
(42.7% <10 mm and 42.7% conical) and 27  4 mm (25-
30 mm) in diameter; infrarenal neck angulation was 24  15
(13-34) degrees. The number of EndoAnchors deployed was
5.8 2.1 (4-7).Technical successwas achieved in 303 patients
(95.0%) andprocedural success in 279patients (87.5%), 217of
240 (89.7%) and 62 of 77 (80.5%) in the primary and revision
arms, respectively. There were 29 residual type Ia endoleaks
(9.1%) at the end of the procedure. During mean follow-up of
9.3  4.7 months, 301 patients (94.4%) were free from sec-
ondary procedures. Among the 18 secondary procedures,
eight were performed for residual type Ia endoleaks and the
others were unrelated to EndoAnchors. There were no open
surgical conversions, there were no aneurysm-related deaths,
and no aneurysm ruptured during follow-up.
Conclusions: Use of EndoAnchors to treat existing and acute
type Ia endoleaks and endograft migration was successful in
most cases. Prophylactic use of EndoAnchors in patients with
hostile aortic neck anatomy appears promising, but deﬁnitive
conclusions must await longer term follow-up data.Outcomes after abdominal aortic aneurysm repair
requiring a suprarenal cross-clamp
Sarah M., Wartman, Karen Woo, Andrew Yaeger,
Michael Sigman, S. Grace Huang, Sung Wan Ham,
Vincent Rowe, Fred A., Weaver
Objective: The objective of this study was to analyze the
early and late outcomes of patients who require a
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an abdominal aortic aneurysm (AAA).
Methods: Patients from 1998 to 2012 who required a
suprarenal aortic cross-clamp during elective open AAA
repair were reviewed. Data abstracted included demo-
graphics and comorbidities; preoperative, perioperative,
and late renal function; late interventions related to AAA
repair; and late mortality. A decrease in renal function was
deﬁned as a >30% decline in estimated glomerular ﬁltration
rate (eGFR) compared with the preoperative value. Primary
outcomes included renal function, intervention-free sur-
vival, and overall survival.
Results: During the study period, 211 patients underwent
open elective or urgent AAA repair; 69 required a supra-
renal cross-clamp. The mean age was 71 years, and 80%
were men. The mean preoperative creatinine concentration
was 1.2 mg/dL, and the mean preoperative eGFR was
66 mL/min/1.73 m2. Location of the aortic cross-clamp was
suprarenal (37), supramesenteric (21), and supraceliac (11).
Perioperatively, 21 patients (30%) experienced a signiﬁcant
decrease in eGFR; four patients required hemodialysis. Six
patients had full recovery of renal function by discharge.
Perioperative morbidity and mortality were 35% and 4%,
respectively. At a mean follow-up of 3 years, seven patients
had an eGFR signiﬁcantly less than the preoperative value.
Late interventions related to the AAA repair were required
in eight patients. Indications included wound complication
(3), anastomotic aneurysm (2), incisional hernia (1), anas-
tomotic graft stenosis (1), and proximal aortic dilation (1).
Overall 5-year intervention-free survival was 62% and
overall survival 77%. Intervention-free survival was
enhanced by antiplatelet use (P = .04), whereas overall
survival was decreased by chronic obstructive pulmonary
disease (P = .003) and perioperative pneumonia (P = .001).
Conclusions: More than a quarter of patients requiring a
suprarenal cross-clamp during open AAA repair experience
renal dysfunction. Late graft-related complications are few,
with preoperative and perioperative pulmonary function
negatively affecting overall patient survival.Percutaneous thoracic endovascular aortic repair is not
contraindicated in obese patients
Jason Zakko, Salvatore Scali, Adam W., Beck,
Charles T., Klodell, Thomas M., Beaver, Tomas D., Martin,
Thomas S., Huber, Robert J., Feezor
Objective: There are limited data describing the preclose
technique with the Perclose ProGlide device (Abbott Vas-
cular, Redwood City, Calif) in percutaneous thoracic endo-
vascular aortic repair (P-TEVAR), particularly in obese
patients, in whom use of this technique is thought to be
relatively contraindicated. The purpose of this analysis was
to describe our experience with P-TEVAR and to compare
outcomes in patients with or without obesity.
Methods: All TEVAR procedures at a single institution from
2005 to 2011 were reviewed, and P-TEVAR patients were
stratiﬁed by body mass index (obesity > 30 kg/m2).Preoperative computed tomography scans were analyzed for
access vessel depth, calciﬁcation, and morphology. Technical
success was deﬁned as the ability to achieve hemostasis and
to maintain limb perfusion without the need for common
femoral artery exposure or obligate surgical repair of the
vessel within a 30-day postoperative period. Generalized
estimating equations and stepwise logistic regression were
used to develop prediction models of preclose failure.
Results: The review identiﬁed 536 patients, in whom 355
(66%) P-TEVAR procedures were completed (366 arteries; n =
40 [11%] bilateral). Compared with nonobese patients (n =
264), obese patients (n = 91) were typically younger (59 
16 years vs 66 16 years; P = .0004) and more likely to have
renal insufﬁciency (28% vs 17%; P = .05) or diabetes mellitus
(19% vs 9%; P = .02). The number of Perclose deployments
was similar between groups (P = NS).Mean sheath size (25.4F
vs 25.0F; P = .04), access vessel inner diameters (8.5 
1.9 mm vs 7. 9  2.0 mm; P = .02), and vessel depth (5 0 
20 mm vs 30  13 mm; P < .0001) were greater in obese
patients. Adjunctive iliac stents were used in 7% of cases (10
[11%] in obese patients vs 16 [6%] in nonobese patients; P =
.2). Overall technical success was 92% (92% for nonobese
patients vs 93% for obese patients; P = .7). Three patients
required subsequent operations for access complications,
two obese patients (2%) and one nonobese patient (0.4%)
(P = .3). Independent predictors of failure were adjunctive
iliac stent (odds ratio [OR], 9.5; 95% conﬁdence interval [CI],
3.3-27.8; P < .0001), more than two Perclose devices (OR,
7.0; 95% CI, 2.3-21; P = .0005), and smaller access vessel
diameter to sheath size ratio (OR multiplies by 1.1 for each
.01 decrease in ratio; 95% CI, 1.02-1.2; P = .007) (area under
the receiver operating characteristic curve = .75).
Conclusions: Obesity is not a contraindication to P-TEVAR.
P-TEVAR can be performed safely, despite the need for
larger diameter sheaths. However, patients predicted to
need adjunctive stenting or possessing smaller access vessel
diameter to sheath size ratios are at highest risk of preclose
failure with the Perclose ProGlide device, and selective use
of this technique is recommended.Predicted shortfall in open aneurysm experience for
vascular surgery trainees
Anahita Dua, Gilbert R., Upchurch, Jason T., Lee, John Eidt,
Sapan S., Desai
Objective: Since the introduction of endovascular aneurysm
repair (EVAR), the volume of open aneurysm repair (OAR)
has steadily declined since 2000. The introduction of next-
generation devices and branched and fenestrated endograft
technology continues to increase the anatomic applicability
of EVAR, further decreasing the need for OAR. This study
models the decline in OAR and uses historical trends to
forecast future decline in volume and its potential effect on
vascular surgery training.
Methods: An S-curve modiﬁed logistic function was used to
model the effect of introducing a new technology (EVAR) on
the standard management of abdominal aortic aneurysm
480 Abstracts(AAA) with OAR starting in the year 2000, when an Inter-
national Classiﬁcation of Diseases, Ninth Revision, code was
ﬁrst introduced for EVAR. Patients who underwent EVAR
and OAR for AAA were determined using the Nationwide
Inpatient Sample from 1998 to 2011.Weighted samples and
data from the United States Census Bureau were used to
extrapolate these numbers to estimate population statistics.
The number of cases completed at teaching hospitals was
calculated using the Nationwide Inpatient Sample, and
Accreditation Council for Graduate Medical Education case
logs were used to forecast the number of cases completed
by vascular surgery trainees.
Results: The highest number of OAR cases in this study was
42,872 in 2000 compared with just 10,039 in 2011. This was
mirrored by a rise in EVAR from 2358 cases in 2000 (5.2%)
to 35,028 in 2011 (76.5% by volume). Of the OAR volume in
2011, 6055 cases (60.3%) were completed at teaching
institutions. An S-curve model with a correlation coefﬁcient
of R2 = 0.982 predicted 3809 open AAA cases at teaching
hospitals by 2015, 2162 by 2020, and 1231 by 2025. When
compared with the 2011 Accreditation Council for Graduate
Medical Education National Resident Report, vascular sur-
gery residents had 44.4% utilization with regard to OAR
(2690 cases covered of 6055 total). When combined with
the increase in vascular surgery trainees and lower number
of open repairs, vascular fellows will complete about 10
OAR cases in 2015 and ﬁve OAR cases in 2020.
Conclusions: The decreasing number of OAR cases will limit
exposure for vascular trainees, who may be ill equipped to
treat patients who require open repair beyond 2015.
Additional methods for providing OAR training should be
explored.Durability of open popliteal artery aneurysm repair
Bernhard Dorweiler, Abebe Gemechu, Marco Doem-
land, Achim Neufang, Christine Espinola-Klein,
Christian-Friedrich Vahl
Objective: The objective of this study was to analyze our
long-term results after open surgery for popliteal artery
aneurysm.
Methods: Records of patients who received surgery
between 1998 and 2010 were retrieved from a compu-
terized database and analyzed retrospectively. End points of
the study were perioperative mortality and morbidity and
patency and limb salvage rate.
Results: Two hundred and six popliteal aneurysms (median
diameter, 30 mm; interquartile range, 18 mm) were treated
(161 elective, 45 emergent) in 154 patients (mean age, 67
11 years) using vein grafts (82%) via the medial approach
(92%). Above-knee popliteal artery (45%) and below-knee
popliteal artery (65%) were the predominant inﬂow and
outﬂow vessels. The overall surgical mortality was 2% (2%
for elective and 3% for emergent procedures; P = not sig-
niﬁcant). Primary, assisted primary, and secondary patency
rates were 88.1% (73.5%), 92.1% (84.3%), and 96.5%
(89.8%) at 5 (at 10) years, respectively, with no signiﬁcantdifference between elective and emergent surgeries. Limb
salvage rate was signiﬁcantly reduced in the emergent
group vs the elective group with 91.1% vs 98.6% at 5 and
10 years (P = .0049). The rate of freedom from any rein-
tervention was 84.3% at 5 and 69.8% at 10 years,
respectively.
Conclusions: Open surgery for popliteal artery aneurysm is
marked by low perioperative mortality and morbidity and
provides excellent long-term results.The inﬂuence of contralateral occlusion on results of
carotid interventions from the Society for Vascular Surgery
Vascular Registry
Joseph J., Ricotta, Gilbert R., Upchurch, Gregg S., Landis,
Christopher T., Kenwood, Flora S., Siami, Nikolaos Tsilimparis,
John J., Ricotta, Rodney A.,White
Objective: Data on the inﬂuence of contralateral carotid
occlusion (CCO) on carotid endarterectomy (CEA) are con-
ﬂicting and are absent for carotid artery stenting (CAS). This
study evaluated the inﬂuence of CCO on CEA and CAS.
Methods: We evaluated patients with and without CCO in
the Society for Vascular Surgery Vascular Registry. Primary
outcome was a composite of periprocedural death, stroke,
or myocardial infarction (MI) (major adverse cardiovascular
events [MACE]) and its individual components. Further
analysis was done to identify the inﬂuence, if any, of
symptom status on outcomes.
Results: There were 1128 CAS and 666 CEA patients with
CCO. CAS patients were more often symptomatic with a
greater incidence of coronary artery disease, congestive
heart failure, diabetes, chronic obstructive pulmonary dis-
ease, and New York Heart Association class >III. Absolute
risk of periprocedural MACE (2.7% for CAS vs 4.2% for CEA),
death (1.1% for CAS vs 0.7% for CEA), stroke (2.1% for CAS
vs 3.1% for CEA), and MI (0.3% for CAS vs 0.6% for CEA) was
statistically equivalent for both. This equivalence was
maintained when patients with CCO were segregated
according to symptom status and after adjusting for peri-
procedural risk. There were 16,646 patients without con-
tralateral occlusion (5698 CAS; 10,948 CEA). Patients
without contralateral occlusion with CEA have better out-
comes in periprocedural MACE (1.8% for patients without
contralateral occlusion vs 4.2% for patients with CCO), and
stroke (1.1% for patients without contralateral occlusion vs
3.1% for patients with CCO) (P < .0001 for both). In CAS
patients, CCO did not signiﬁcantly affect periprocedural
MACE (3.2% for patients without contralateral occlusion vs
2.7% for patients with CCO), death (0.8% for patients
without contralateral occlusion vs 1.0% for patients with
CCO), stroke (2.3% for patients without contralateral
occlusion vs 2.1% for patients with CCO), or MI (0.6% for
patients without contralateral occlusion vs 0.3% for patients
with CCO). In CEA patients, CCO increased MACE, primarily
by increasing stroke rates in asymptomatic (0.7% vs 2.0%;
P = .0095) and symptomatic (1.7% vs 4.9%; P = .0012)
patients.
European Journal of Vascular and Endovascular Surgery Volume 48 Issue 4 p. 478e481 October/2014 481Conclusions: Although CEA is preferred in patients without
contralateral occlusion, regardless of symptom status, based
on lower rates of periprocedural MACE, death, and stroke,
the beneﬁt of CEA is lost in patients with CCO because of
increased stroke rates in CCO patients after CEA but not
after CAS regardless of symptom status. The results of CAS
and CEA in patients with CCO are equivalent and within
acceptable American Heart Association guidelines.Patients carrying CYP2C19 loss of function alleles have a
reduced response to clopidogrel therapy and a greater risk
of in-stent restenosis after endovascular treatment of
lower extremity peripheral arterial disease
Baolei Guo, Qiwen Tan, Daqiao Guo, Zhenyu Shi,
Chunyan Zhang, Wei Guo
Objective: This study evaluated the relationship between
the cytochrome P450 (CYP) 2C19 genotype and the anti-
platelet effect of clopidogrel therapy and investigated
whether genotyping can predict the risk of ischemic events
after endovascular treatment (ET) of lower extremity
peripheral arterial disease.
Methods: From January 2011 to July 2012, 120 consecutive
patients with arteriosclerosis obliterans (TransAtlantic Inter-
Society Consensus for the Management of Peripheral
Arterial Disease [TASC II] A-C) in the superﬁcial femoral
artery were included in a prospectively maintained data-
base. Patients received 75 mg clopidogrel and 100 mg
aspirin daily for at least 5 days before TaqMan (Life Tech-
nologies, Grand Island, NY) of CYP2C19 single-nucleotide
polymorphisms and thromboelastography of the clopidogrel
response. ET was subsequently performed, and follow-up
evaluations, including duplex ultrasound imaging and ankle-
brachial index assessment, were performed at 1, 3, 6, and12 months after ET. During the follow-up, stent patency was
assessed by ultrasound imaging, computed tomography
angiography, or digital subtraction angiography.
Results: A total of 74 ET procedures were performed. Fifty
of the enrolled patients (41.7%) completed the follow-up
examinations and were included in the analysis. The mean
duration of follow-up was 9.8  2.1 months (range, 1-
30 months). Carriers of at least one CYP2C19 loss-of-
function (LOF) allele had a diminished pharmacodynamic
response to clopidogrel (51.6  20.1 vs 39.8  15.2 for
patients without and with LOF alleles, respectively; P =
.022). Carriers of one LOF allele had an increased incidence
of ischemic events compared with patients without any
LOF alleles (59.0% vs 20.8%, respectively; P = .008). This
trend was even more evident in patients with two LOF
alleles compared with patients with no LOF alleles (100%
vs 20.8% ischemic events; P = .002). The cumulative pri-
mary patency rate at 12 months was 56.0%, with sig-
niﬁcant differences between groups (73.1% vs 34.6% in
patients without and with LOF alleles, respectively; P =
.0.006). CYP2C19 LOF carrier status was associated with an
increased rate of primary end points (P = .007). On the
basis of their adenosine diphosphate-induced platelet
aggregation, patients with high platelet reactivity had a
signiﬁcantly higher risk of ischemic events (P = .012).
CYP2C19 genotypic classiﬁcation (adjusted hazard ratio,
2.688; 95% conﬁdence interval, 1.366-5.288; P = .004) and
history of smoking (adjusted hazard ratio, 2.430; 95%
conﬁdence interval, 1.024-5.765; P = .044) were inde-
pendent risk factors for ischemic events.
Conclusions: CYP2C19 LOF alleles were associated with a
diminished platelet response to clopidogrel treatment.
Patients carrying CYP2C19 LOF alleles who are treated
with clopidogrel may trend toward a poor prognosis
after ET.
